Therapeutics News and Research

RSS

New challenges to military medicine

Better body armor and rapid aeromedical evacuations enable American service members to survive blasts that would have proved fatal in Vietnam or even the first Gulf War, but they pose new challenges to military medicine - how to deal with the excruciating pain of injuries, especially severe burns from IED blasts that body armor can't protect.

13 May 2013

DURECT: Pfizer provides update on investigational drug Remoxy

DURECT Corporation today announced that Pfizer has provided an update on Remoxy as part of their Form 10-Q filing.

10 May 2013

Echo Therapeutics reports net loss of $7.0 million for first quarter 2013

Echo Therapeutics, Inc., a company developing its needle-free Symphony CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced financial results for the quarter ended March 31, 2013.

10 May 2013

Drug resistant brain tumors: an interview with Prof. Mischel, Ludwig Institute for Cancer Research and Prof. Bensinger, University of California

In cancer, mutations in proteins that control cell growth are common, leading to unrestrained cellular proliferation and tumor formation.

9 May 2013

Precision Therapeutics to present clinical data of ChemoFx chemoresponse assay at WAGO meeting

Precision Therapeutics, Inc., a life science company that develops personalized medicine products for individualizing cancer care, today announced that a clinical study which demonstrates the feasibility of the ChemoFx chemoresponse assay to identify patients unlikely to respond to first-line therapy has been accepted for presentation at the 2013 Annual Meeting of the Western Association of Gynecologic Oncologists.

9 May 2013

Phase 1b clinical study data of EBI-005 for treatment of dry eye disease presented at ARVO meeting

Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today the presentation of data for EBI-005, the first IL-1 (Interleukin-1) signaling inhibitor designed for topical ocular administration, at the Association for Research in Vision and Ophthalmology 2013 Annual Meeting in Seattle, Washington.

9 May 2013

Elixir Medical receives FDA approval to initiate patient enrollment in EXCELLA III clinical trial in US

Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that it has received approval from the Food and Drug Administration to initiate patient enrollment in the EXCELLA III clinical trial in the United States at up to 50 institutions with conditions to be addressed in parallel.

8 May 2013

New treatment could potentially benefit Irish SLE patients, find researchers

Researchers from the Royal College of Surgeons in Ireland have discovered that a new treatment for the inflammatory condition, Systemic Lupus Erythmstosus could potentially benefit Irish patients who suffer from the condition.

8 May 2013

Biomedical engineers grow 3D human heart muscle that acts just like natural tissue

Duke University biomedical engineers have grown three-dimensional human heart muscle that acts just like natural tissue. This advancement could be important in treating heart attack patients or in serving as a platform for testing new heart disease medicines.

7 May 2013

Targacept reports net loss of $8.1 million in first quarter 2013

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the first quarter ended March 31, 2013.

7 May 2013

Aileron Therapeutics concludes first-in-human study of ALRN-5281 Stapled Peptide drug

Aileron Therapeutics, Inc. today announced the completion of the first-in-human study of its lead Stapled Peptide drug, ALRN-5281, a proprietary, long-acting growth-hormone-releasing hormone (GHRH) agonist for treating orphan endocrine disorders, including adult growth hormone (GH) deficiency and human immunodeficiency virus (HIV) lipodystrophy, as well as broader patient populations involving a wide variety of metabolic/endocrine diseases.

7 May 2013

Entremed reports patent issuance for its lead drug candidate ENMD-2076

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, today announced the issuance by the Chinese State Intellectual Property Office of Patent Certificate No. ZL 200680044656.7.

7 May 2013

Neuroperspective reviews status and prospects of therapeutics for Parkinson's disease

NI Research, the leading publisher of independent research on the neurotherapeutics industry, has released the May issue of NeuroPerspective, which reviews the status and prospects of therapeutics for Parkinson's.

7 May 2013

Researchers explore biological processes of stem cell division

The human body contains trillions of cells, all derived from a single cell, or zygote, made by the fusion of an egg and a sperm. That single cell contains all the genetic information needed to develop into a human, and passes identical copies of that information to each new cell as it divides into the many diverse types of cells that make up a complex organism like a human being.

6 May 2013

Novel screening method for identifying inhibitors of EZH2 methyltransferase

Tumor repressor genes, which inhibit tumor formation, can be "turned off" due to undesirable molecular changes affecting the chromosomes on which the genes reside. Understanding and being able to control these alterations could lead to new approaches for activating or inactivating genes linked to cancer.

5 May 2013

EntreMed announces issuance of patent for clinical-stage compound, 2-methoxyestradiol

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced the issuance of a U.S. patent covering methods of treatment and formulations for its clinical-stage compound, 2-methoxyestradiol.

3 May 2013

TSRI scientists find dissimilar genes that keep very similar shapes

Solving the structure of a critical human molecule involved in cancer, scientists at The Scripps Research Institute have found what they call a good example of structural conservation-dissimilar genes that keep very similar shapes.

2 May 2013

Scientists study repeating patterns in nature to better understand role of immune system in cancer

Can the patterns in tree branches or the meandering bends in a river provide clues that could lead to better cancer therapies? According to a new study from Virginia Commonwealth University Massey Cancer Center, these self-similar, repeating patterns in nature known as fractals help scientists better understand how the immune system is organized and may one day be used to help improve stem cell transplant outcomes in leukemia patients by predicting the probability of transplant complications.

2 May 2013

Findings set the stage for identifying potential new drug targets, treatment strategies for AML

nvestigators for The Cancer Genome Atlas Research Network have detailed and broadly classified the genomic alterations that frequently underlie the development of acute myeloid leukemia, a deadly cancer of the blood and bone marrow.

2 May 2013

Details about genomic landscapes of AML and endometrial cancer revealed

Two studies from The Cancer Genome Atlas program reveal details about the genomic landscapes of acute myeloid leukemia and endometrial cancer.

2 May 2013

Therapeutics News and Research

New challenges to military medicine

DURECT: Pfizer provides update on investigational drug Remoxy

Echo Therapeutics reports net loss of $7.0 million for first quarter 2013

Drug resistant brain tumors: an interview with Prof. Mischel, Ludwig Institute for Cancer Research and Prof. Bensinger, University of California

Precision Therapeutics to present clinical data of ChemoFx chemoresponse assay at WAGO meeting

Phase 1b clinical study data of EBI-005 for treatment of dry eye disease presented at ARVO meeting

Elixir Medical receives FDA approval to initiate patient enrollment in EXCELLA III clinical trial in US

New treatment could potentially benefit Irish SLE patients, find researchers

Biomedical engineers grow 3D human heart muscle that acts just like natural tissue

Targacept reports net loss of $8.1 million in first quarter 2013

Aileron Therapeutics concludes first-in-human study of ALRN-5281 Stapled Peptide drug

Entremed reports patent issuance for its lead drug candidate ENMD-2076

Neuroperspective reviews status and prospects of therapeutics for Parkinson's disease

Researchers explore biological processes of stem cell division

Novel screening method for identifying inhibitors of EZH2 methyltransferase

EntreMed announces issuance of patent for clinical-stage compound, 2-methoxyestradiol

TSRI scientists find dissimilar genes that keep very similar shapes

Scientists study repeating patterns in nature to better understand role of immune system in cancer

Findings set the stage for identifying potential new drug targets, treatment strategies for AML

Details about genomic landscapes of AML and endometrial cancer revealed

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News